Shorts Ease but Analysts Trim After TVTX's Rough Month

Travere Therapeutics heads into the final stretch of Q4 with a split picture: short sellers have quietly covered a significant chunk of their position, but the stock has shed 13% over the past month and Guggenheim has just trimmed its target, leaving analysts and investors debating whether the FILSPARI growth story is durable enough to close a 50% gap to consensus value.

The most striking development in the short book is how rapidly bears have retreated. Short interest peaked near 13 million shares in late September and has since fallen to 10.9 million, putting it at 12.2% of the free float, a drop of roughly 16% month-on-month. That is a material covering move, and despite the high absolute level the direction of travel is clearly bullish from a supply-of-short perspective. The borrow market reinforces this: cost to borrow has dipped below 0.5% and availability is exceptionally loose at 2,414% of shares currently short, meaning there are roughly 24 shares available to lend for every one already borrowed. The ORTEX short score has also eased from 57.5 in late October to 53.7, moving toward neutral. Options positioning adds a mild supportive note: the put/call ratio is 0.52, slightly below its 20-day average of 0.57 and well off the 1.53 reading that marked the year's high. None of these signals points to aggressive new short conviction at current levels.

The Street remains broadly constructive, though the week's one fresh action points the other way. Guggenheim analyst Vamil Divan cut his price target to $78 from $89 on November 4, while keeping a Buy rating. The mean consensus target still stands at $75, against a close of $49.41, implying roughly 52% upside on paper. Bulls anchor their case on FILSPARI's commercial momentum: second-quarter revenue hit $141.1 million with 2,012 new patient start forms, physician adoption in both IgA nephropathy and FSGS is rising, and a newly allowed USPTO patent is expected to extend exclusivity to October 2037. Bears worry that the $489 million cash balance may not stretch far enough to fund the full pipeline without a dilutive offering, and that any setback with FILSPARI or pegtibatinase would remove the main thesis. Valuation sits at 10.9x trailing earnings and 8.4x book, with EV/EBITDA at 12.5x, up sharply over the past week as the stock slid.

One real-economy data point adds texture to the commercial picture. Medicaid prescriptions for the company's drugs have risen for three consecutive quarters, and the most recent reading of 906 prescriptions in Q1 2026 is 27% above the same quarter a year earlier. That trend corroborates the physician survey data cited in analyst notes, though it covers only the Medicaid channel and there is no measured link between this series and the company's reported financials.

Insider activity over the period is mechanically interesting but should be read carefully. CEO Eric Dube executed a series of option exercises and open-market sales on October 15, netting roughly $13.1 million in sale proceeds against $3.0 million in exercise costs. All transactions were filed under a pre-arranged 10b5-1 plan, meaning they were scheduled well in advance rather than reflecting a fresh view on the stock. The 90-day insider net across the company runs to roughly minus $64.7 million in value, almost entirely reflecting these plan-driven CEO sales rather than discretionary conviction selling. Among institutions, Janus Henderson remains the largest holder at 12% of shares, with BlackRock, Fidelity and Vanguard Capital each holding between 5% and 9%. There are no 13D activists on the register.

The next earnings print is on February 18, 2027, leaving 106 days for the FILSPARI growth trajectory and the pending CEO transition to Bradley Campbell to shape sentiment. The stock's most recent post-earnings move was a decline of roughly 1.9% in the session following the November 2 release, a mild reaction that suggests the quarter landed broadly in line. What to watch from here is whether the Guggenheim target cut proves an outlier or the start of a broader Street recalibration, and whether the covering trend in short interest continues as the new year approaches.